Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 7/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9283797 | 0.98 | GBA1 (0.47) | GBA1ALDH1A1KCNH2BCHEPTGER4 | |
| SCHEMBL3147824 | 0.88 | FKBP1A (0.40) | ALDH1A1 | |
| SCHEMBL9342486 | 0.84 | L3MBTL1 (0.41) | GBA1ALDH1A1KCNH2 | |
| SCHEMBL9770467 | 0.81 | TERT (0.33) | — | |
| SCHEMBL3911411 | 0.81 | ACE (0.39) | ALDH1A1 | |
| SCHEMBL5049189 | 0.81 | L3MBTL1 (0.37) | BCHE | |
| SCHEMBL7156001 | 0.80 | ALDH1A1 (0.43) | GBA1ALDH1A1BCHE | |
| Acetic Acid SCHEMBL29252348 | 0.78 | GBA1 (0.46) | GBA1ALDH1A1KCNH2BCHE | |
| SCHEMBL15655931 | 0.77 | PTPN1 (0.34) | ALDH1A1 | |
| SCHEMBL9316281 | 0.77 | GBA1 (0.54) | GBA1ALDH1A1KCNH2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222261-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-12-24 | — | — | US | disclosed |
| CN-101511429-A | Indulines derivatives and gpr119 agonists | SMITHKLINE BEECHAM CORP (US) | 2009-08-19 | — | — | CN | disclosed |
| EP-2043744-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008008895-A1 | GPR119 AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008887-A2 | GPR119 AGONISTS FOR TREATING METABOLIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-17 | — | — | WO | disclosed |
| JP-2004123871-A | DETERGENT COMPOSITION | ASAHI KASEI CHEMICALS CORP | 2004-04-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GPR119, GOT2, SLC5A2 | GBA1 639/4885ALDH1A1 350/4885KCNH2 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.